Evaluating how pediatric cancer patients respond to the flu vaccine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the immunogenicity of the seasonal influenza vaccine in pediatric oncology patients, specifically those diagnosed with hematological malignancies. The study will be conducted in two stages, starting with a feasibility phase to determine the viability of a larger longitudinal study. Participants will have blood samples collected up to six times over the course of a year to measure their immune response to the vaccine. Additionally, information regarding their underlying health conditions and flu testing will be gathered from medical records.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient ≤ 18 years old at the time of consent receiving care at St. Jude Children's Research Hospital
* Diagnosed with a hematological malignancy
* Eligible to receive the current seasonal influenza vaccine

Exclusion Criteria:

• Previously received at least one dose of the current seasonal influenza vaccine.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Ramilo Octavio, MD — St. Jude Children's Research Hospital
• Study coordinator: Ramilo Octavio, MD
• Email: referralinfo@stjude.org
• Phone: 866-278-5833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• FaceSay: a computer program to help kids recognize facial expressions and improve social interactions

  A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07923370

• Access to Innovative Cancer Treatments for Children and Young People in Belgium

  This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT07727694

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.